According to SIGA Technologies's latest financial reports the company's total assets are $0.25 B. A companyโs total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Year | Total assets | Change |
---|---|---|
2023-12-31 | $0.25 B | 30.41% |
2022-12-31 | $0.19 B | -9.17% |
2021-12-31 | $0.21 B | 43.31% |
2020-12-31 | $0.14 B | -24.54% |
2019-12-31 | $0.19 B | -2.4% |
2018-12-31 | $0.20 B | 40.63% |
2017-12-31 | $0.14 B | -10.13% |
2016-12-31 | $0.16 B | -13.33% |
2015-12-31 | $0.18 B | 15.56% |
2014-12-31 | $0.16 B | -17.07% |
2013-12-31 | $0.19 B | 83.14% |
2012-12-31 | $0.10 B | 17.1% |
2011-12-31 | $90.38 M | 234.35% |
2010-12-31 | $27.03 M | 4.31% |
2009-12-31 | $25.91 M | 194.58% |
2008-12-31 | $8.79 M | -16.92% |
2007-12-31 | $10.58 M | -24.52% |
2006-12-31 | $14.02 M | 129.77% |
2005-12-31 | $6.1 M | -0.09% |
2004-12-31 | $6.11 M | 0.18% |
2003-12-31 | $6.09 M | 115.53% |
2002-12-31 | $2.82 M | -32.74% |
2001-12-31 | $4.2 M |
Company | Total assets | differencediff. | Country |
---|---|---|---|
Sarepta Therapeutics
SRPT | $3.26 B | 1,183.48% | ๐บ๐ธ USA |
Novavax NVAX | $1.79 B | 606.69% | ๐บ๐ธ USA |
Celldex Therapeutics CLDX | $0.46 B | 83.06% | ๐บ๐ธ USA |
NanoViricides NNVC | $13.4 M | -94.73% | ๐บ๐ธ USA |
BioCryst Pharmaceuticals
BCRX | $0.51 B | 103.25% | ๐บ๐ธ USA |
Emergent BioSolutions
EBS | $1.82 B | 616.80% | ๐บ๐ธ USA |